Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of 60-minute Elotuzumab Infusion in Multiple Myeloma
NCT02159365Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2014
- Primary completion
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Started Mar 2014; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02159365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02159365.